Literature DB >> 12941846

The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation.

Ariel N Rad1, Gabriele Pollara, S M Afzal Sohaib, Cheryl Chiang, Benjamin M Chain, David R Katz.   

Abstract

Dendritic cells (DCs) respond to danger signals from tissue injury by amplifying their immune-inducing capacity. In the cancer context, this may lead to in vivo antitumor synergism between DCs and DNA-damaging chemotherapeutic agents. Neither the interaction between DCs and dying tumor cells nor whether different ways of inducing cell injury can deliver danger signals of different strength to DCs nor the potential role of damaged DNA as a danger signal has been studied rigorously. Here we report that coculture of immature DCs with tumor cells treated with the alkylating agents melphalan and chlorambucil leads to enhanced autologous and allogeneic T-cell activation, up-regulation of surface expression of MHC and costimulatory molecules, and increased interleukin (IL)-12 secretion. Exposure of the same DCs to tumor cells killed by cytarabine or by freeze-thaw (primary necrosis) resulted in significantly less T-cell proliferation and IL-12 production, indicating that DCs are able to sense and respond differentially to the mode of cell death. Exposure of DCs to DNA purified from tumor cells treated with alkylating agents also increased their T-cell-stimulating capacity, expression of CD86, and IL-12 secretion, supporting the hypothesis that the activating effects of tumor cells are linked to the nature of the DNA damage. This is the first study that shows that DCs respond differentially to killed tumor cells, depending upon the mechanism of DNA damage and consequent cell death.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941846

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

Review 1.  Natural endogenous adjuvants.

Authors:  Kenneth L Rock; Arron Hearn; Chun-Jen Chen; Yan Shi
Journal:  Springer Semin Immunopathol       Date:  2004-10-14

2.  Regulation of dendritic cell interleukin-12 secretion by tumour cell necrosis.

Authors:  H Kandil; V Bachy; D J Williams; R Helmi; F M Gotch; M A A Ibrahim
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

3.  Transcriptional and functional defects of dendritic cells derived from the MUTZ-3 leukaemia line.

Authors:  Jane Rasaiyaah; Mahdad Noursadeghi; Paul Kellam; Benjamin Chain
Journal:  Immunology       Date:  2009-07       Impact factor: 7.397

4.  Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.

Authors:  Cheryl Lai-Lai Chiang; Andrea R Hagemann; Rachel Leskowitz; Rosemarie Mick; Thomas Garrabrant; Brian J Czerniecki; Lana E Kandalaft; Daniel J Powell; George Coukos
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

5.  Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.

Authors:  Robbert G van der Most; Andrew J Currie; Amanda L Cleaver; Joanne Salmons; Anna K Nowak; Sathish Mahendran; Irma Larma; Amy Prosser; Bruce W S Robinson; Mark J Smyth; Anthony A Scalzo; Mariapia A Degli-Esposti; Richard A Lake
Journal:  PLoS One       Date:  2009-09-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.